PF 04418948
Modify Date: 2024-01-04 19:46:20
PF 04418948 structure
|
Common Name | PF 04418948 | ||
|---|---|---|---|---|
| CAS Number | 1078166-57-0 | Molecular Weight | 409.407 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 639.1±55.0 °C at 760 mmHg | |
| Molecular Formula | C23H20FNO5 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 340.3±31.5 °C | |
Use of PF 04418948PF-04418948 is a novel, potent and selective prostaglandin EP2 receptor antagonist with IC50 of 16 nM, displays >2000-fold functional selectivity for the human EP2 receptor over antagonist activity against the human EP1, EP3, EP4, DP1 and CRTH2 receptors.IC50 value: 16 nMTarget: EP2in vitro: PF-04418948 inhibits prostaglandin E2 (PGE2)-induced increase in cAMP in cells expressing EP2 receptors with a functional KB value of 1.8 nM. In human myometrium, PF-04418948 produced a parallel, rightward shift of the butaprost-induced inhibition of the contractions induced by electrical field stimulation with an apparent KB of 5.4 nM. [1]in vivo: In dog bronchiole and mouse trachea, PF-04418948 produced parallel rightward shifts of the PGE2-induced relaxation curve with a KB of 2.5 nM and an apparent KB of 1.3 nM respectively. Reversal of the PGE2-induced relaxation in the mouse trachea by PF-04418948 produced an IC50 value of 2.7 nM. Given orally, PF-04418948 attenuated the butaprost-induced cutaneous blood flow response in rats. [1] PF-04418948 competitively inhibits relaxations of murine and guinea pig trachea induced by ONO-AE1-259 and PGE2 respectively.[2] |
| Name | 1-(4-fluorobenzoyl)-3-[(6-methoxynaphthalen-2-yl)oxymethyl]azetidine-3-carboxylic acid |
|---|---|
| Synonym | More Synonyms |
| Description | PF-04418948 is a novel, potent and selective prostaglandin EP2 receptor antagonist with IC50 of 16 nM, displays >2000-fold functional selectivity for the human EP2 receptor over antagonist activity against the human EP1, EP3, EP4, DP1 and CRTH2 receptors.IC50 value: 16 nMTarget: EP2in vitro: PF-04418948 inhibits prostaglandin E2 (PGE2)-induced increase in cAMP in cells expressing EP2 receptors with a functional KB value of 1.8 nM. In human myometrium, PF-04418948 produced a parallel, rightward shift of the butaprost-induced inhibition of the contractions induced by electrical field stimulation with an apparent KB of 5.4 nM. [1]in vivo: In dog bronchiole and mouse trachea, PF-04418948 produced parallel rightward shifts of the PGE2-induced relaxation curve with a KB of 2.5 nM and an apparent KB of 1.3 nM respectively. Reversal of the PGE2-induced relaxation in the mouse trachea by PF-04418948 produced an IC50 value of 2.7 nM. Given orally, PF-04418948 attenuated the butaprost-induced cutaneous blood flow response in rats. [1] PF-04418948 competitively inhibits relaxations of murine and guinea pig trachea induced by ONO-AE1-259 and PGE2 respectively.[2] |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 639.1±55.0 °C at 760 mmHg |
| Molecular Formula | C23H20FNO5 |
| Molecular Weight | 409.407 |
| Flash Point | 340.3±31.5 °C |
| Exact Mass | 409.132538 |
| PSA | 76.07000 |
| LogP | 3.08 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.639 |
| Storage condition | -20℃ |
| RIDADR | NONH for all modes of transport |
|---|
|
~83%
PF 04418948 CAS#:1078166-57-0 |
| Literature: Pfizer Inc Patent: US2008/280877 A1, 2008 ; Location in patent: Page/Page column 22 ; US 20080280877 A1 |
![ethyl 1-(4-fluorobenzoyl)-3-{[(6-methoxy-2-naphthyl)oxy]methyl}azetidine-3-carboxylate structure](https://image.chemsrc.com/caspic/370/1078166-69-4.png)
| Precursor 1 | |
|---|---|
| DownStream 0 | |
| 1-(4-Fluorobenzoyl)-3-{[(6-methoxy-2-naphthyl)oxy]methyl}-3-azetidinecarboxylic acid |
| pf-04418948 |
| 3-Azetidinecarboxylic acid, 1-(4-fluorobenzoyl)-3-[[(6-methoxy-2-naphthalenyl)oxy]methyl]- |
| unii-i7z38e70vf |